Pharmaceutical Strategic Alliances - Maximizing returns from collaborative development and commercialization

In today’s competitive environment, alliances are critical for pharmaceutical companies to optimize R&D and marketing synergies and share risks in order to develop pipelines. Companies must maximize their licensing and alliance management capabilities in order to bring new drugs to the market successfully while minimizing the potential for failure.

Pharmaceutical Strategic Alliances provides case studies and in-depth analysis focusing on deal outcomes, and highlights key success factors in agreeing and executing strategic alliances. The report isolates four key alliance structures - co-commercialization, co-development, multi-product, joint ventures - and provides 14 detailed case studies of major strategic alliances signed and completed over the past 20 years including:

» Genentech and Roche

» Vertex and Novartis

» Millennium and Ortho Biotech

» LeukoSite, Ilex Oncology and Schering AG

» Amylin and Eli Lilly

Each case study provides in-depth analysis of:

Historical company development, performance, the partnering structure dynamics, and the commercial and strategic outcomes of the alliance for each partner.

Specific deal terms from regulatory Securities and Exchange Commission filings and press releases, and interviews with leading executives involved in the deal.

Partnering structures used by the collaborating companies researched through governance agreements, outlining specific responsibilities and the organisation and management of joint committees.

The relative success or failure of each venture, along with key drivers, enabling you to form successful pharmaceutical alliances in the future.

This report will provide you with the tools to evaluate and recommend successful pharmaceutical alliances in the future.

Published: September 2006 Format PDF
Table of Contents
Full Table of Contents
Price: $2,875.00 / GBP1,897.50